Frazier Life Sciences Management’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.2M Buy
+900,080
New +$34.4M 0.72% 26

Other funds holding CLDX

Frazier Life Sciences Management's CLDX Position: Q3 2026 in Review

Frazier Life Sciences Management opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 900,080 shares worth $29.2M. The stake represents 0.72% of the portfolio and ranks #26 among its holdings.

249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Frazier Life Sciences Management held 900,080 shares of Celldex Therapeutics worth $29.2M as of Q3 2026.
  • Celldex Therapeutics was a new Frazier Life Sciences Management position in Q3 2026.
  • Celldex Therapeutics made up 0.72% of Frazier Life Sciences Management's portfolio in Q3 2026, its #26 holding.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Frazier Life Sciences Management's 13F filing for Q3 2026, filed 16 Nov 2026.